Federation Des Caisses Desjardins Du Quebec Jounce Therapeutics, Inc. Transaction History

Federation Des Caisses Desjardins Du Quebec

  • $18.4 Billion
  • Q4 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2017

Aug 30, 2024
SELL
$12.52 - $17.82 $165,589 - $235,687
-13,226 Closed
0 $0
Q3 2017

Aug 30, 2024
BUY
$11.17 - $16.99 $83,350 - $126,779
7,462 Added 129.46%
13,226 $207 Million
Q2 2017

Aug 30, 2024
BUY
N/A
5,764
5,764 $80.9 Million

Others Institutions Holding JNCE

# of Institutions
4
Shares Held
720K
Call Options Held
0
Put Options Held
0
View Full List

About Jounce Therapeutics, Inc.

JNCE Quotes by TradingView
  • Ticker JNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,694,200
  • Description
  • Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...
More about JNCE
Track This Portfolio

Track Federation Des Caisses Desjardins Du Quebec Portfolio

Follow Federation Des Caisses Desjardins Du Quebec and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email